Protagonist Therapeutics (Australia)

Protagonist Therapeutics (Australia) is identified in Wikidata as a company in Brisbane, Australia. The official Protagonist Therapeutics website describes Protagonist as a clinical-stage biopharmaceutical company focused on peptide drug discovery and development, targeting areas of unmet need across rare and prevalent diseases where treatments are limited or inadequate. The site lists U.S. FDA approvals of MIMRYLO™ (rusfertide) and ICOTYDE™ (icotrokinra), and identifies Dinesh Patel as CEO and Arturo Molina, MD, as Chief Medical Officer.

Protagonist Therapeutics (Australia) is recorded in Wikidata as a company in Brisbane, Australia. The official Protagonist Therapeutics website presents Protagonist as a clinical-stage biopharmaceutical company that seeks to improve patients’ lives through peptide drug discovery and development, targeting areas of unmet need across rare and prevalent diseases where treatments are limited or inadequate. The site lists U.S. FDA approval of MIMRYLO™ (rusfertide) and U.S. FDA approval of ICOTYDE™ (icotrokinra), and identifies Dinesh Patel as CEO and Arturo Molina, MD, as Chief Medical Officer.

Clinical-stage biopharmaceutical company focused on peptide drug discovery and development for areas of unmet need.

• MIMRYLO™ (rusfertide)

• ICOTYDE™ (icotrokinra)

• 2021.09.07

  Reported2021.09.07

  Protagonist Therapeutics appoints Scott Plevy to lead gastroenterology[5]Protagonist Therapeutics 任命 Scott Plevy 负责胃肠病学业务prnewswire.com

  Protagonist Therapeutics announced the appointment of Scott Plevy, M.D., as Executive Vice President and Therapeutic Head, Gastroenterology. He will oversee clinical operations and development of the company's gastrointestinal disease programs.

• 2021.06.15

  Reported2021.06.16

  Protagonist Therapeutics prices $115 million public offering[6]Protagonist Therapeutics为1.15亿美元公开发行定价prnewswire.com

  Protagonist Therapeutics announced the pricing of an underwritten public offering of 3,046,358 common shares at $37.75 per share, with gross proceeds expected to be approximately $115 million before expenses. The offering was expected to close on or about June 18, subject to customary conditions.

Read more

1. 1Protagonist Therapeutics Inc.protagonist-inc.com
2. 2Events & Presentations - Protagonist Therapeutics Inc.protagonist-inc.com
3. 3Corporate Presentationprotagonist-inc.com
4. 4Protagonist Therapeutics (Australia)wikidata.org
5. 5Protagonist Therapeutics 任命 Scott Plevy 负责胃肠病学业务prnewswire.com
6. 6Protagonist Therapeutics为1.15亿美元公开发行定价prnewswire.com